Full text not available from this repository.

Abstract

Inflammatory bowel disease (IBD), classified as a global disease in the 21st century, comprises Crohn's disease (CD) and ulcerative colitis (UC), and is manifested by chronic inflammation of the gastrointestinal tract of unknown etiology. The step-up approach is effective for inducing remission and controlling inflammation, whereas the top-down therapy appears to be a better solution for the maintenance of remission with an improved bowel function. A systematic search was performed in Ovid MEDLINE and Embase (1946-December 2018) to identify relevant trials that support medication therapy in IBD. Thirty-nine potential trials were retrieved, of which 29 focused on CD, and 10 studied UC. There is mounting evidence on both benefits and disadvantages in the application of early initiation of top-down therapy in suitably selected patients. Nevertheless, there are uncertainties about the appropriateness of these approaches for the management of IBD and there are conflicting results in overall outcomes including mucosal healing and rehospitalization. The choice of either top-down or step-up therapy in the treatment of IBD should be an individualized approach and cannot be recommended as a part of a generalized guideline. Further prospective studies are warranted to determine whether combination therapy or aggressive therapy is superior to monotherapy.

Item Type:	Article
Authors/Creators:	Salahudeen, MS
Keywords:	Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Step-up therapy; Top-down therapy; Gastrointestinal disorders
Journal or Publication Title:	Drugs of Today
Publisher:	Clarivate Analytics
ISSN:	1699-3993
DOI / ID Number:	https://doi.org/10.1358/dot.2019.55.6.2969816
Copyright Information:	Copyright 2019 Clarivate Analytics
Related URLs:	Google Scholar: Salahudeen, MS
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page